126 related articles for article (PubMed ID: 38623978)
21. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report.
Wang J; Li X; Zhou J; Qiu D; Zhang M; Sun L; Li SC
Front Oncol; 2023; 13():1043244. PubMed ID: 37091182
[TBL] [Abstract][Full Text] [Related]
23. Primary pulmonary lymphoepithelioma-like carcinoma: A case report of pathological complete response (pCR) by neoadjuvant treatment.
Zhang L; Hao T; Wei Y; Dong M; Xiong Y
Medicine (Baltimore); 2021 Mar; 100(11):e24987. PubMed ID: 33725970
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
25. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature.
Tang Z; Fang R; Tong G; Liu P; Ou Z; Tang Y
Lung Cancer; 2020 Aug; 146():335-340. PubMed ID: 32623076
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
29. Anlotinib plus camrelizumab achieved long-term survival in a patient with metastatic esophageal neuroendocrine carcinoma.
Zhou L; Xu G; Chen T; Wang Q; Zhao J; Zhang T; Duan R; Xia Y
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1855. PubMed ID: 37381647
[TBL] [Abstract][Full Text] [Related]
30. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
Jiang Y; Zhang L; Zhu F; Zhu H; Cao X; Zhang Y
Ann Palliat Med; 2022 Mar; 11(3):1135-1146. PubMed ID: 35365044
[TBL] [Abstract][Full Text] [Related]
31. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Jiang T; Chen J; Xu X; Cheng Y; Chen G; Pan Y; Fang Y; Wang Q; Huang Y; Yao W; Wang R; Li X; Zhang W; Zhang Y; Hu S; Guo R; Shi J; Wang Z; Cao P; Wang D; Fang J; Luo H; Geng Y; Xing C; Lv D; Zhang Y; Yu J; Cang S; Zhang Y; Zhang J; Yang Z; Shi W; Zou J; Zhou C; Ren S
Mol Cancer; 2022 Jan; 21(1):4. PubMed ID: 34980131
[TBL] [Abstract][Full Text] [Related]
32. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
33. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.
Tang L; Chen N; He W; Zhou J; Zhang J; Lin Z; Wang Z; Hao J; Lin F
PLoS One; 2020; 15(10):e0240729. PubMed ID: 33064745
[TBL] [Abstract][Full Text] [Related]
34. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S; Chan SL; Gu S; Bai Y; Ren Z; Lin X; Chen Z; Jia W; Jin Y; Guo Y; Hu X; Meng Z; Liang J; Cheng Y; Xiong J; Ren H; Yang F; Li W; Chen Y; Zeng Y; Sultanbaev A; Pazgan-Simon M; Pisetska M; Melisi D; Ponomarenko D; Osypchuk Y; Sinielnikov I; Yang TS; Liang X; Chen C; Wang L; Cheng AL; Kaseb A; Vogel A;
Lancet; 2023 Sep; 402(10408):1133-1146. PubMed ID: 37499670
[TBL] [Abstract][Full Text] [Related]
35. Lymphoepithelioma-like carcinoma in liver not associated with Epstein-Barr virus: a report of 3 cases and literature review.
Zhang K; Tao C; Tao Z; Wu F; An S; Wu J; Rong W
Diagn Pathol; 2020 Sep; 15(1):115. PubMed ID: 32967689
[TBL] [Abstract][Full Text] [Related]
36. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
37. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.
Wen Y; Dong Y; Yi L; Yang G; Xiao M; Li Q; Zhao C; Ye D; Yao Y
Front Oncol; 2023; 13():1241475. PubMed ID: 37920159
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
39. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease.
Zhou N; Lin Y; Peng X; Wang Y; Wang Y
Lung Cancer; 2019 Dec; 138():116-123. PubMed ID: 31683094
[TBL] [Abstract][Full Text] [Related]
40. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Li T; Hu W; Jin L; Yin X; Kang D; Piao L
Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
